Clinical Trial Update: Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant breast cancer trial compares nab-paclitaxel plus carboplatin versus nab-paclitaxel plus epirubicin; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Epirubicin (epirubicin)
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Hebei Medical University Fourth Hospital | Conditions: Breast Cancer, Triple-negative Breast Cancer | Phase 2 | Status: RECRUITING